Bionano is a hyper-technological industry that operates at the level of the human genome.
It has developed a platform with an unprecedented ability to detect structural variations in DNA molecules, is active in research for the fight against cancer and other genetic diseases.
It presented excellent results days ago and now a category of big investors has started...
The founding team members at 180 Life Sciences Corp. (NASDAQ: ATNF) are the recognized pioneers of research and development in anti-inflammatory therapeutics.
180 Life Sciences is a clinical-stage biotechnology company that brings together the expertise of world-renowned scientists to develop and test novel treatments for inflammation and is currently working in...
Neurocrine Biosciences Inc. (NASD:NBIX) will replace O-I Glass Inc. (NYSE:OI) in the S&P MidCap 400, and O-I Glass will replace HMS Holdings Corp (NASD:HMSY) in the S&P SmallCap 600 effective prior to the opening of trading on Tuesday, March 30.
Cellect Biotechnology and Quoin Pharmaceuticals Announce Strategic Merger
Up to $25 million of funding at $75 million pre-money valuation to be available to the combined company concurrently with the merger
Cellect shareholders to retain 25% of the combined Company pre-funding
Quoin has secured $25 million in committed equity funding from Altium Capital, a...
First time an antigen presenting cell (APC) activator has shown an Overall Survival (OS) benefit in a randomised setting in metastatic breast cancer patients known to be insensitive to immune checkpoint inhibitor therapy
Promising and improving overall trend in OS in total population (based on approx. 60% of events): median survival benefit of +2.7 months from...
ProQR Announces Positive Results from Clinical Trial of QR-421a in Usher Syndrome and Plans to Start Pivotal Trials.
QR-421a demonstrated a concordant benefit in multiple measures of vision, including best corrected visual activity (BCVA), static perimetry, and retinal imaging (OCT)
QR-421a observed to be well tolerated with no serious adverse events...
Voltron Therapeutics, Inc. Announces Positive Data from Animal Testing of Self-Assembling Vaccine in the Fight Against COVID-19
today announced positive data from its second set of preclinical animal testing of its HaloVax™ Self-Assembling Vaccine (SAV) against COVID-19.
Benitec Shares Skyrocket as Morgan Stanley Takes Stake
$BNTC shares blasted higher Tuesday after disclosing in a regulatory filing that Morgan Stanley has a 5.2% stake in the genetic drug company.
The stake amounts to 249,174 shares, or about $1.51 million.
Benitec‘s “proprietary platform, called DNA-directed RNA interference, or ddRNAi, combines RNA...
Clovis Oncology’s Rubraca® (rucaparib) Significantly Improves Progression-Free Survival versus Chemotherapy in Patients with Later-line Ovarian Cancer Associated with a BRCA Mutation
The ARIEL4 study met its primary endpoint, showing a statistically significant improvement in investigator-assessed progression-free survival (PFS) for Rubraca versus...
Immatics Presents Data Update on Dose Escalation from Ongoing ACTengine® Cell Therapy Programs
·First anti-tumor activity observed in heavily pre-treated solid cancer patients during early phases of dose escalation
·Tumor shrinkage observed in 8 out of 10 patients including one partial response consistent with robust biological activity of infused T cell...
Zhongchao Renews Contract with China Association of Health Promotion and Education and GlaxoSmithKline
Extending the Cooperation in Pulmonary Arterial Hypertension
$ZCMD yesterday announced the renewal of its partnership with the China Association for Health Promotion and Education and GlaxoSmithKline (China) Investment Limited to continue the medical education...
Can-Fite Signs $42.7 Million Out-Licensing Deal with Ewopharma
Swiss Ewopharma to market Piclidenoson and Namodenoson in Central Eastern Europe (CEE)
$2.25 million upfront payment with an additional $40.45 million for regulatory & sales milestones and 17.5% royalties are included
Rubius Therapeutics Reports Initial Clinical Data from Ongoing Phase 1/2 Trial of RTX-240 in Patients with Advanced Solid Tumors, Demonstrating Single-Agent Activity.
RTX-240 Generated Partial Responses in Metastatic Anal Cancer and Metastatic Uveal Melanoma Patients; No DLTs or Related Grade 3/4 Adverse Events
RTX-240 Promoted Trafficking of NK and T Cells...
INVO Bioscience Expands Company-Owned Clinic Opportunity Under Amended U.S. Commercialization Agreement
$INVO today announced an amendment under its exclusive U.S. commercialization agreement with Ferring Pharmaceuticals. The amendment provides for an increase in the number of INVO company-owned clinics initially allowable under the agreement and removes certain...
Shares of $SEEL skyrocketed today after BTIG initiated coverage on the stock with a buy recommendation and a one-year price target nearly 4.7 times higher than Seelos' closing price on Thursday.
BTIG analyst Robert Hazlett likes the prospects for Seelos' pipeline. Last week, the biotech announced that it had completed enrollment in a pivotal proof-of-concept...
Entera Bio Ltd Announces Positive Topline EB613 Phase 2 Biomarker Data
‒ Trial Met Primary Endpoint of Significant Increase in P1NP Based on Final Analysis of 3 Month Data
‒ Final Analysis of 6-Month Data, Including Change in Bone Mineral Density, Expected in Q2:21
‒ The trial’s primary endpoint was met - the complete 3-month results from the trial showed a...
NLS Pharmaceutics Obtains License to Full Regulatory Data Package and Proprietary Know-How for Sanorex® (Mazindol)
Agreement provides exclusive rights to all available data included in the original new drug application ("NDA") for mazindol in the U.S.
$NLSP announces that it has entered into a License Agreement (the "Agreement") with Novartis Pharma AG, whereby...